Table 1 Baseline characteristics in predicted 10-y ASCVD risk (n = 4057)
From: External validation of pooled cohort equations using systolic blood pressure intervention trial data
< 5% | 5–7.5% | 7.5–10% | > 10% | |
|---|---|---|---|---|
Patients no. (%) | 165 (4.0) | 319 (7.9) | 447 (11.0) | 3126 (77.0) |
Age, mean (SD) | 55.1 (3.7) | 57.6 (4.4) | 59.6 (5.1) | 66.4 (7.6) |
African-Americans, no. (%) | 43 (26.0) | 113 (35.4) | 198 (44.3) | 1249 (40.0) |
Men, no. (%) | 26 (15.8) | 103 (32.3) | 199 (44.5) | 2139 (68.4) |
Systolic blood pressure, mean (SD) (mmHg) | 130.0 (15.1) | 134.1 (14.0) | 134.7 (13.7) | 142.8 (15.5) |
Anti-hypertensive medication, no. (%) | 146 (88.5) | 262 (82.1) | 370 (82.8) | 2726 (87.2) |
TC, mean (SD) (mg/dL) | 207.5 (33.7) | 203.5 (32.9) | 200.0 (31.5) | 201.1 (31.4) |
HDL-C, mean (SD) (mg/dL) | 57.4 (18.1) | 55.4 (14.9) | 54.1 (15.5) | 53.0 (15.0) |
LDL-C, mean (SD) (mg/dL) | 125.2 (26.9) | 124.3 (27.6) | 122.2 (26.7) | 122.9 (27.2) |